Takeda Pharmaceutical Company Limited (TYO:4502)
4,288.00
+120.00 (2.88%)
Apr 18, 2025, 3:30 PM JST
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 49,281 employees as of March 31, 2024. The number of employees increased by 186 or 0.38% compared to the previous year.
Employees
49,281
Change (1Y)
186
Growth (1Y)
0.38%
Revenue / Employee
92.92M JPY
Profits / Employee
4.22M JPY
Market Cap
6,532.12B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Chugai Pharmaceutical | 7,778 |
Daiichi Sankyo Company | 18,726 |
HOYA Corporation | 35,702 |
Otsuka Holdings | 35,338 |
Astellas Pharma | 14,754 |
Olympus | 28,838 |
Shionogi & | 4,959 |
Sysmex | 10,042 |
Takeda Pharmaceutical Company News
- 11 days ago - BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 - Accesswire
- 17 days ago - Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns - Seeking Alpha
- 5 weeks ago - Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
- 6 weeks ago - Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - Benzinga
- 6 weeks ago - Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera - Business Wire
- 7 weeks ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - Benzinga
- 7 weeks ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 2 months ago - Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued - Seeking Alpha